Literature DB >> 26192258

Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance?

Prassannah Satasivam1, Bing Ying Poon2, Behfar Ehdaie1, Andrew J Vickers2, James A Eastham3.   

Abstract

PURPOSE: We evaluated whether initial diagnostic parameters could predict the confirmatory biopsy result in patients initiating active surveillance for prostate cancer, to determine whether some men at low risk for disease reclassification could be spared unnecessary biopsy.
MATERIALS AND METHODS: The cohort included 392 men with Gleason 6 prostate cancer on initial biopsy undergoing confirmatory biopsy. We used univariate and multivariable logistic regression to assess if high grade cancer (Gleason 7 or greater) on confirmatory biopsy could be predicted from initial diagnostic parameters (prostate specific antigen density, magnetic resonance imaging result, percent positive cores, percent cancer in positive cores and total tumor length).
RESULTS: Median patient age was 62 years (IQR 56-66) and 47% of patients had a dominant or focal lesion on magnetic resonance imaging. Of the 392 patients 44 (11%) had high grade cancer on confirmatory biopsy, of whom 39 had Gleason 3+4, 1 had 4+3, 3 had Gleason 8 and 1 had Gleason 9 disease. All predictors were significantly associated with high grade cancer at confirmatory biopsy on univariate analysis. However, in the multivariable model only prostate specific antigen density and total tumor length were significantly associated (AUC 0.85). Using this model to select patients for confirmatory biopsy would generally provide a higher net benefit than performing confirmatory biopsy in all patients, across a wide range of threshold probabilities.
CONCLUSIONS: If externally validated, a model based on initial diagnostic criteria could be used to avoid confirmatory biopsy in many patients initiating active surveillance.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biopsy; prostatic neoplasms; watchful waiting

Mesh:

Year:  2015        PMID: 26192258      PMCID: PMC4840176          DOI: 10.1016/j.juro.2015.07.078

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  24 in total

1.  Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.

Authors:  Ashley E Ross; Stacy Loeb; Patricia Landis; Alan W Partin; Jonathan I Epstein; Anna Kettermann; Zhaoyong Feng; H Ballentine Carter; Patrick C Walsh
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

2.  Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging.

Authors:  Vincent Fradet; John Kurhanewicz; Janet E Cowan; Alexander Karl; Fergus V Coakley; Katsuto Shinohara; Peter R Carroll
Journal:  Radiology       Date:  2010-05-26       Impact factor: 11.105

3.  Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.

Authors:  Ryan K Berglund; Timothy A Masterson; Kinjal C Vora; Scott E Eggener; James A Eastham; Bertrand D Guillonneau
Journal:  J Urol       Date:  2008-09-17       Impact factor: 7.450

4.  Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.

Authors:  Ari Adamy; David S Yee; Kazuhito Matsushita; Alexandra Maschino; Angel Cronin; Andrew Vickers; Bertrand Guillonneau; Peter T Scardino; James A Eastham
Journal:  J Urol       Date:  2010-12-17       Impact factor: 7.450

5.  Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.

Authors:  Ignacio F San Francisco; Lillian Werner; Meredith M Regan; Marc B Garnick; Glenn Bubley; William C DeWolf
Journal:  J Urol       Date:  2010-12-17       Impact factor: 7.450

6.  Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer.

Authors:  Hebert Alberto Vargas; Oguz Akin; Asim Afaq; Debra Goldman; Junting Zheng; Chaya S Moskowitz; Amita Shukla-Dave; James Eastham; Peter Scardino; Hedvig Hricak
Journal:  J Urol       Date:  2012-09-25       Impact factor: 7.450

7.  Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study.

Authors:  David Margel; Stanley A Yap; Nathan Lawrentschuk; Laurence Klotz; Masoom Haider; Karen Hersey; Antonio Finelli; Alexandre Zlotta; John Trachtenberg; Neil Fleshner
Journal:  J Urol       Date:  2012-02-14       Impact factor: 7.450

8.  Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.

Authors:  Meelan Bul; Xiaoye Zhu; Riccardo Valdagni; Tom Pickles; Yoshiyuki Kakehi; Antti Rannikko; Anders Bjartell; Deric K van der Schoot; Erik B Cornel; Giario N Conti; Egbert R Boevé; Frédéric Staerman; Jenneke J Vis-Maters; Henk Vergunst; Joris J Jaspars; Petra Strölin; Erik van Muilekom; Fritz H Schröder; Chris H Bangma; Monique J Roobol
Journal:  Eur Urol       Date:  2012-11-12       Impact factor: 20.096

9.  Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance.

Authors:  A F Kotb; S Tanguay; M A Luz; W Kassouf; A G Aprikian
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-10-12       Impact factor: 5.554

Review 10.  Systematic review of complications of prostate biopsy.

Authors:  Stacy Loeb; Annelies Vellekoop; Hashim U Ahmed; James Catto; Mark Emberton; Robert Nam; Derek J Rosario; Vincenzo Scattoni; Yair Lotan
Journal:  Eur Urol       Date:  2013-06-04       Impact factor: 20.096

View more
  6 in total

1.  Prostate cancer: Avoiding excess confirmatory biopsies.

Authors:  Clemens Thoma
Journal:  Nat Rev Urol       Date:  2015-08-04       Impact factor: 14.432

Review 2.  Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and Radiotherapy Treatment Planning.

Authors:  Drew Moghanaki; Baris Turkbey; Neha Vapiwala; Behfar Ehdaie; Steven J Frank; Patrick W McLaughlin; Mukesh Harisinghani
Journal:  Semin Radiat Oncol       Date:  2016-08-31       Impact factor: 5.934

3.  Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?

Authors:  Pietro Pepe; Antonio Garufi; Giandomenico Priolo; Michele Pennisi
Journal:  World J Urol       Date:  2015-12-23       Impact factor: 4.226

Review 4.  MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?

Authors:  Ivo G Schoots
Journal:  Transl Androl Urol       Date:  2018-02

5.  Difference of opinion - Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: Yes.

Authors:  Henk G van der Poel; Roderick C N van den Bergh
Journal:  Int Braz J Urol       Date:  2016 May-Jun       Impact factor: 1.541

6.  Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.

Authors:  Rajiv Jayadevan; Ely R Felker; Lorna Kwan; Danielle E Barsa; Haoyue Zhang; Anthony E Sisk; Merdie Delfin; Leonard S Marks
Journal:  JAMA Netw Open       Date:  2019-09-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.